Keele Research Repository

Article

Winkelsas, AM, Grunseich, C, Harmison, GG, Chwalenia, K, Rinaldi, C, Hammond, SM, Johnson, K, Bowerman, M ORCID: https://orcid.org/0000-0002-3579-6403, Arya, S, Talbot, K, Wood, MJ and Fischbeck, KH (2021) Targeting the 5’ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. Molecular Therapy: Nucleic Acids, 23. pp. 731-742.

Wood, MJA, Talbot, K and Bowerman, M (2017) Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Human Molecular Genetics, 26 (R2). R151 - R159.

Bowerman, M, Becker, CG, Yáñez-Muñoz, RJ, Ning, K, Wood, MJA, Gillingwater, TH, Talbot, K and UK SMA Research Consortium, . (2017) Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Disease Models and Mechanisms, 10 (8). 943 - 954.

Hammond, SM, Hazell, G, Shabanpoor, F, Saleh, AF, Bowerman, M, Sleigh, JN, Meijboom, KE, Zhou, H, Muntoni, F, Talbot, K, Gait, MJ and Wood, MJA (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113 (39). 10962 - 10967.